This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Celldex Therapeutics Announces Issuance Of Seminal Patent For CD27 Agonists

PHILLIPSBURG, N.J., July 10, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent No: 8,481,029 entitled "Human immune therapies using a CD27 agonist alone or in combination with other immune modulators" which broadly supports the Company's product candidate CDX-1127. CD27, a signaling molecule expressed on T lymphocytes, can be effectively manipulated with activating antibodies to induce potent anti-tumor responses and, due to the restricted expression and regulation of CD27, may result in less toxicity—overcoming a key barrier that other targets in this class have faced. CDX-1127 is a fully human monoclonal antibody (mAb) that targets CD27 and is currently in Phase 1 clinical development for the treatment of solid tumors and hematologic malignancies.

The patent is assigned to the University of Southampton and Celldex has an exclusive license to this patent based on the execution of an exclusive licensing agreement with the University of Southampton to develop human antibodies to CD27 in November 2008. The patent includes 18 claims covering various methods of treating cancer using agonistic anti-human CD27 antibodies and relates, among other things, directly to Celldex's CD27 antibody program and therapeutic uses of Celldex's antibody CDX-1127.

"We continue to make excellent progress advancing CDX-1127 and securing this key piece of intellectual property is an important achievement as we expand our clinical program in solid tumors and complete dose-escalation studies in hematologic malignancies," said Tibor Keler, Senior Vice President and Chief Scientific Officer of Celldex Therapeutics. "This patent also directly speaks to the importance of the innovative work of Professor Martin Glennie and his team at the University of Southampton in targeting members of the TNF receptor superfamily—which we believe is resulting in rapid translation of exciting immunostimulatory antibodies into the clinic."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs